Addex Therapeutics (ADXN) Intangibles (2024 - 2025)
Addex Therapeutics (ADXN) posted Intangibles of -$228148.3 for Q4 2025, down 9.61% sequentially from -$208154.2 in Q4 2024, and down 9.61% YoY from -$252391.6 in Q4 2024.
Addex Therapeutics (ADXN) Intangibles (2024 - 2025) Analysis & Trends
Addex Therapeutics has reported Intangibles for 2 years, with the latest figure at -$228148.3 in Q4 2025.
- Quarterly Intangibles fell 9.61% year-over-year to -$228148.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$228148.3 (down 9.61% YoY) and the FY2025 annual result came in at -$219935.1, down 6.11% from the prior year.
- Intangibles retreated to -$228148.3 in Q4 2025 per ADXN's latest filing, from -$208154.2 in the prior quarter.
- Over five years, Intangibles peaked at $80616.8 in Q2 2024 and troughed at -$228148.3 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -228,148.31 |
| Dec 31, 2024 | -208,154.23 |
| Sep 30, 2024 | 25,028.98 |
| Jun 30, 2024 | 80,616.77 |